Santalum album cream - Santalis Healthcare

Drug Profile

Santalum album cream - Santalis Healthcare

Alternative Names: Albuterpenoid; East Indian sandalwood oil; EISO; SAN 007; VIR 003; VIR 007

Latest Information Update: 12 May 2017

Price : $50

At a glance

  • Originator ViroXis
  • Developer Santalis Healthcare Corporation; Santalis Pharmaceuticals
  • Class Anti-infectives; Phytotherapies; Skin disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Atopic dermatitis; Molluscum contagiosum
  • Phase I Human papillomavirus infections; Poxvirus infections

Most Recent Events

  • 24 May 2017 ViroXis plans a phase II trial for Condylomata acuminata in USA (Topical) (NCT03158974)
  • 09 May 2017 Phase-II clinical trials in Atopic dermatitis (In adults) in USA (Topical)
  • 09 May 2017 Santalis Pharmaceuticals plans a phase III trial for Human papillomavirus infection (In children) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top